Clinuvel Scenesse yields positive data in EPP
According to the company, Scenesse is the first photoprotective drug developed as a prophylactic treatment for phototoxicity experienced by patients with EPP, a rare light intolerance disease. CUV029,
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.
Both the companies collaborate on ProteoTech’s small molecule technology platform against misfolded proteins to work on its alpha-synuclein therapeutic program. Michael J. Fox Foundation for Parkinson’s Research has